LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Malignant Melanoma Releases MicroRNAs to Condition the Dermis Prior to Metastasis

By LabMedica International staff writers
Posted on 01 Sep 2016
Print article
Image: A lymph node with almost complete replacement by metastatic melanoma (Photo courtesy of Wikimedia Commons).
Image: A lymph node with almost complete replacement by metastatic melanoma (Photo courtesy of Wikimedia Commons).
Cancer researchers have discovered that prior to spreading, malignant melanoma sends out packets of microRNAs to induce morphological changes in the dermis to prepare that tissue to receive and transport the cancer cells.

Melanoma originates in the epidermis and becomes metastatic after invasion into the dermis. However, the interaction between melanoma cells and dermis has not been well studied.

Investigators at Tel Aviv University (Israel) have significantly changed that situation with their report, published in the August 22, 2016, online edition of the journal Nature Cell Biology, that melanoma cells directly affected the formation of the dermal tumor niche by microRNA trafficking before invasion.

MicroRNAs (miRNAs) are a small noncoding family of 19- to 25-nucleotide RNAs that regulate gene expression by targeting mRNAs in a sequence specific manner, inducing translational repression or mRNA degradation, depending on the degree of complementarity between miRNAs and their targets. Many miRNAs are conserved in sequence between distantly related organisms, suggesting that these molecules participate in essential processes. In fact, miRNAs have been shown to be involved in the regulation of gene expression during development, cell proliferation, apoptosis, glucose metabolism, stress resistance, and cancer.

Melanocytes, cells of melanoma origin, are specialized in releasing pigment vesicles, termed melanosomes. In melanoma in situ, the investigators found melanosome markers in distal fibroblasts before melanoma invasion. The melanosomes carried microRNAs into primary fibroblasts triggering changes, including increased proliferation, migration, and pro-inflammatory gene expression, all known features of cancer-associated fibroblasts (CAFs). Specifically, melanosomal microRNA-211 directly targeted IGF2R (Insulin-like growth factor 2 receptor) and led to MAPK (Mitogen-activated protein kinase) signaling activation, which reciprocally encouraged melanoma growth.

The investigators identified two compounds that could prevent conditioning of the dermis by melanosome miRNAs. These potential drugs were SB202190, which inhibited the delivery of the melanosomes from the tumor to the dermis, and U0126, which prevented the morphological changes in the dermis even after the arrival of the melanosomes.

"The threat of melanoma is not in the initial tumor that appears on the skin, but rather in its metastasis - in the tumor cells sent off to colonize in vital organs like the brain, lungs, liver, and bones," said senior author Dr. Carmit Levy, researcher in the department of human molecular genetics and biochemistry at Tel Aviv University. "We have discovered how the cancer spreads to distant organs and found ways to stop the process before the metastatic stage. Our study is an important step on the road to a full remedy for the deadliest skin cancer. We hope that our findings will help turn melanoma into a nonthreatening, easily curable disease."

Related Links:
Tel Aviv University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more